Arbutus Biopharma Current Ratio 2008-2021 | ABUS

Arbutus Biopharma current ratio from 2008 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Arbutus Biopharma Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.08B $0.01B 9.44
2021-03-31 $0.14B $0.01B 20.52
2020-12-31 $0.13B $0.01B 13.39
2020-09-30 $0.12B $0.01B 15.94
2020-06-30 $0.09B $0.01B 13.52
2020-03-31 $0.09B $0.00B 21.91
2019-12-31 $0.09B $0.01B 11.99
2019-09-30 $0.09B $0.01B 10.70
2019-06-30 $0.10B $0.01B 11.32
2019-03-31 $0.11B $0.01B 12.75
2018-12-31 $0.13B $0.01B 11.50
2018-09-30 $0.14B $0.01B 11.37
2018-06-30 $0.16B $0.01B 13.67
2018-03-31 $0.18B $0.01B 16.85
2017-12-31 $0.13B $0.02B 8.84
2017-09-30 $0.09B $0.01B 11.03
2017-06-30 $0.11B $0.01B 8.92
2017-03-31 $0.12B $0.01B 11.06
2016-12-31 $0.13B $0.01B 12.52
2016-09-30 $0.15B $0.01B 18.09
2016-06-30 $0.17B $0.01B 16.67
2016-03-31 $0.18B $0.01B 15.73
2015-12-31 $0.18B $0.01B 17.38
2015-09-30 $0.20B $0.01B 14.46
2015-06-30 $0.22B $0.02B 13.37
2015-03-31 $0.24B $0.03B 9.64
2014-12-31 $0.12B $0.02B 5.76
2014-09-30 $0.11B $0.02B 5.73
2014-06-30 $0.12B $0.02B 7.20
2014-03-31 $0.14B $0.02B 5.95
2013-12-31 $0.07B $0.01B 5.62
2013-09-30 $0.04B $0.01B 3.10
2013-06-30 $0.05B $0.01B 3.75
2013-03-31 $0.05B $0.01B 3.99
2012-12-31 $0.05B $0.01B 4.68
2012-09-30 $0.01B $0.01B 0.98
2012-06-30 $0.01B $0.01B 1.45
2012-03-31 $0.01B $0.01B 1.64
2011-12-31 $0.01B $0.01B 1.69
2011-09-30 $0.01B $0.01B 1.96
2011-06-30 $0.02B $0.01B 1.92
2011-03-31 $0.01B $0.01B 1.98
2010-12-31 $0.02B $0.01B 2.20
2010-09-30 $0.02B $0.01B 1.92
2010-06-30 $0.02B $0.01B 2.35
2010-03-31 $0.02B $0.01B 4.19
2009-12-31 $0.02B $0.01B 3.81
2009-09-30 $0.03B $0.01B 4.22
2009-06-30 $0.03B $0.01B 5.14
2009-03-31 $0.03B $0.00B 5.74
2008-12-31 $0.03B $0.01B 6.75
2008-09-30 $0.04B $0.01B 6.41
2008-06-30 $0.04B $0.01B 5.06
2008-03-31 $0.02B $0.01B 4.14
2007-12-31 $0.02B $0.01B 3.61
2007-09-30 $0.02B $0.01B 3.61
2007-06-30 $0.02B $0.01B 3.09
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.400B $0.007B
Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76